2020
DOI: 10.1039/d0nj00974a
|View full text |Cite
|
Sign up to set email alerts
|

Whole-genome sequence analysis and homology modelling of the main protease and non-structural protein 3 of SARS-CoV-2 reveal an aza-peptide and a lead inhibitor with possible antiviral properties

Abstract: SARS-CoV-2 3CLpro shows homology in binding to an aza-peptide epoxide (APE) known for the irreversible inhibition of main peptidase in SARS-CoV.

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 39 publications
0
12
0
Order By: Relevance
“…To better understand the molecular flexibility of RmSBP, we believe that the equilibrium molecular dynamics simulations at growth temperatures are definitely worthwhile. Of note, RmSBP shows sequence similarity of 20% with the ORF1ab polyprotein of SARS-CoV-2 (strain SARS-CoV-2_HKU-SZ-001_2020), and was, therefore, recently used as a template for modeling structures [ 21 ]. Although the sequence similarity of amino acids is not high between RmSBP and ORF1ab polyprotein in SARS-CoV-2, our structural results for RmSBP will help to understand the model structure of ORF1ab of SARS-CoV-2.…”
Section: Discussionmentioning
confidence: 99%
“…To better understand the molecular flexibility of RmSBP, we believe that the equilibrium molecular dynamics simulations at growth temperatures are definitely worthwhile. Of note, RmSBP shows sequence similarity of 20% with the ORF1ab polyprotein of SARS-CoV-2 (strain SARS-CoV-2_HKU-SZ-001_2020), and was, therefore, recently used as a template for modeling structures [ 21 ]. Although the sequence similarity of amino acids is not high between RmSBP and ORF1ab polyprotein in SARS-CoV-2, our structural results for RmSBP will help to understand the model structure of ORF1ab of SARS-CoV-2.…”
Section: Discussionmentioning
confidence: 99%
“…The proteases of novel coronavirus share high percentage of sequence and structure similarity with SARS coronavirus which has the main role in the processing of viral polyprotein. These proteins perform stripping ubiquitin to help in evading immune response of the host (Shanker et al., 2020 ). Small molecules and drug inhibitors can be designed to block the cascade signaling pathways to protect the host system.…”
Section: Introductionmentioning
confidence: 99%
“…This is crucial for designing new drugs. An example to this is the study by Shankar et al which suggested two ligands that can possibly be developed into antivirals against SARS-CoV-2, the first (an aza-peptide epoxide) can be used to irreversibly inhibit viral protease and the second as a viral replication inhibitor [ 60 ]. Another study used computer-aided drug design to identify a mechanism-based inhibitor of SARS-CoV-2 Mpro and screened more than 10,000 compounds for their ability to inhibit this protease [ 63 ].…”
Section: Treatment and Drug Discoverymentioning
confidence: 99%
“…It was also shown to antagonize host innate immunity. [ 47 , 59 , 60 ] nsp4 500 aa (residues K2764 – Q3263) A multipass membrane protein responsible for membrane rearrangement. It interacts with nsp3 and 6 to form double membrane vesicles (DMV).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation